Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hepatitis HELP
Based on 56,306 articles published since 2007
|||| 11 

These are the 56306 published articles about Hepatitis that originated from Worldwide during 2007-2018.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. 2018

Schillie, Sarah / Vellozzi, Claudia / Reingold, Arthur / Harris, Aaron / Haber, Penina / Ward, John W / Nelson, Noele P. ·Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC. · University of California, Berkeley School of Public Health, Berkeley, California. · Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC. ·MMWR Recomm Rep · Pubmed #29939980.

ABSTRACT: HEPATITIS B VIRUS (HBV) IS TRANSMITTED VIA BLOOD OR SEXUAL CONTACT. PERSONS WITH CHRONIC HBV INFECTION ARE AT INCREASED RISK FOR CIRRHOSIS AND LIVER CANCER AND REQUIRE MEDICAL CARE. THIS REPORT UPDATES AND SUMMARIZES PREVIOUSLY PUBLISHED RECOMMENDATIONS FROM THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) AND CDC REGARDING THE PREVENTION OF HBV INFECTION IN THE UNITED STATES. ACIP RECOMMENDS TESTING ALL PREGNANT WOMEN FOR HEPATITIS B SURFACE ANTIGEN (HBSAG), AND TESTING HBSAG-POSITIVE PREGNANT WOMEN FOR HEPATITIS B VIRUS DEOXYRIBONUCLEIC ACID (HBV DNA); ADMINISTRATION OF HEPB VACCINE AND HEPATITIS B IMMUNE GLOBULIN (HBIG) FOR INFANTS BORN TO HBV-INFECTED WOMEN WITHIN 12 HOURS OF BIRTH, FOLLOWED BY COMPLETION OF THE VACCINE SERIES AND POSTVACCINATION SEROLOGIC TESTING; UNIVERSAL HEPATITIS B VACCINATION WITHIN 24 HOURS OF BIRTH, FOLLOWED BY COMPLETION OF THE VACCINE SERIES; AND VACCINATION OF CHILDREN AND ADOLESCENTS AGED <19 YEARS WHO HAVE NOT BEEN VACCINATED PREVIOUSLY. ACIP RECOMMENDS VACCINATION OF ADULTS AT RISK FOR HBV INFECTION, INCLUDING UNIVERSAL VACCINATION OF ADULTS IN SETTINGS IN WHICH A HIGH PROPORTION HAVE RISK FACTORS FOR HBV INFECTION AND VACCINATION OF ADULTS REQUESTING PROTECTION FROM HBV WITHOUT ACKNOWLEDGMENT OF A SPECIFIC RISK FACTOR. THESE RECOMMENDATIONS ALSO PROVIDE CDC GUIDANCE FOR POSTEXPOSURE PROPHYLAXIS FOLLOWING OCCUPATIONAL AND OTHER EXPOSURES. THIS REPORT ALSO BRIEFLY SUMMARIZES PREVIOUSLY PUBLISHED AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASEST GUIDELINES FOR MATERNAL ANTIVIRAL THERAPY TO REDUCE PERINATAL HBV TRANSMISSION.

2 Guideline Management of special patient groups with hepatitis B virus infection: The EASL 2017 Clinical Practice Guidelines. 2017

Idilman, Ramazan. ·Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. idilman@medicine.ankara.edu.tr. ·Turk J Gastroenterol · Pubmed #29082891.

ABSTRACT: The morbidity and mortality of hepatitis B virus-related liver disease are linked to the persistence of the hepatitis B virus replication. Viral suppression with antiviral therapy has been shown to provide clinical benefits. Several special groups of patients with hepatitis B virus infection require special attention. In this brief report, based on European Association for the Study of the Liver 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, the current optimal management of special patient groups with hepatitis B virus infection is summarized.

3 Guideline The summarized of EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. 2017

Idilman, Ramazan. ·Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. idilman@medicine.ankara.edu.tr. ·Turk J Gastroenterol · Pubmed #28936972.

ABSTRACT: -- No abstract --

4 Guideline Position Paper on Treatment of Hepatitis C in Romania 2017. Part Two. 2017

Gheorghe, Liana / Sporea, Ioan / Iacob, Speranta / Sirli, Roxana / Trifan, Anca / Diculescu, Mircea / Stanciu, Carol / Pascu, Oliviu / Acalovschi, Monica / Brisc, Ciprian / Cijevschi, Cristina / Gheorghe, Cristian / Spârchez, Zeno / Rogoveanu, Ion / Dobru, Daniela / Dumitrascu, Dan L. ·Center for Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. · Department of Gastroenterology and Hepatology, Victor Babeș University of Medicine and Pharmacy, Timișoara, Romania. · Center for Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. msiacob@gmail.com. · Institute of Gastroenterology and Hepatology, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania. · 3rd Medical Clinic, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. · Gastroenterology Department, Faculty of Medicine and Pharmacy, Oradea, Romania. · Gastroenterology Department, University of Medicine and Pharmacy, Craiova, Romania. · Gastroenterology Department, University of Medicine and Pharmacy, Târgu Mureș, Romania. · 2nd Medical Clinic, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. ·J Gastrointestin Liver Dis · Pubmed #28922445.

ABSTRACT: BACKGROUND AND AIMS: Hepatitis C virus (HCV) infection is a common condition with endemic prevalence in some areas of the world. In Romania, the mean prevalence is about 3%. New treatments have become available on the market in recent years and new drugs are in the pipeline. A re-evaluation of HCV therapy was considered mandatory. The Romanian Society of Gastroenterology and Hepatology undertook this task for the practitioners of this country. METHODOLOGY: A group of recognized experts was created who screened the available literature and the major available guidelines. A list of items requiring attention was created and these were discussed and rated. Decisions were taken by consensus. RECOMMENDATIONS: We present here the second part of the Society's recommendations for chronic HCV infection treatment. An agreement between experts was reached regarding the therapy of the special categories of patients infected with HCV, complications and monitoring of the therapy, follow-up of the patients who reached sustained virologic response and re-treatment of the patients with therapy failure. CONCLUSIONS: This Position Paper represents a guide for the assessment and the therapy of HCV infection. The recommendations are in concordance with other guidelines but are applied to real-life conditions in Romania.

5 Guideline Hepatitis B vaccines: WHO position paper – July 2017. 2017

Anonymous7480912. · ·Wkly Epidemiol Rec · Pubmed #28685564.

ABSTRACT: -- No abstract --

6 Guideline Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. 2017

Sarmati, L / Andreoni, M / Antonelli, G / Arcese, W / Bruno, R / Coppola, N / Gaeta, G B / Galli, M / Girmenia, C / Mikulska, M / Pane, F / Perno, C F / Picardi, M / Puoti, M / Rambaldi, A / Svicher, V / Taliani, G / Gentile, G. ·Department of System Medicine, Clinical Infectious Diseases, Tor Vergata University, Rome, Italy. Electronic address: sarmati@med.uniroma2.it. · Department of System Medicine, Clinical Infectious Diseases, Tor Vergata University, Rome, Italy. · Department of Molecular Medicine, 'La Sapienza' University, Rome, Italy. · Department of Hematology, Stem Cell Transplant Unit, Tor Vergata University, Rome, Italy. · Department of Infectious Diseases, Hepatology Outpatients Unit, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy. · Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy. · Infectious Diseases and Viral Hepatitis, Department of Mental and Physical Health and Preventive Medicine, Università della Campania, Naples, Italy. · Infectious Diseases Unit, University of Milan, L. Sacco Hospital, Milan, Italy. · Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa, Azienda Policlinico Umberto I, La Sapienza University, Rome, Italy. · Division of Infectious Diseases, Department of Health Sciences, University of Genoa, Genoa, Italy; Division of Infectious Diseases, IRCCS San Martino University Hospital-IST, Genoa, Italy. · Department of Clinical Medicine and Surgery, Hematology, Federico II University, Naples, Italy. · Department of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy. · Infectious Diseases Department, Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milan, Italy. · Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano, Milan, Italy; Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy. · Clinic of Infectious and Tropical Medicine, Policlinico Umberto I, Rome, Italy. · Department of Cellular Biotechnologies and Hematology, 'La Sapienza' University, Rome, Italy. ·Clin Microbiol Infect · Pubmed #28668466.

ABSTRACT: SCOPE: Hepatitis B virus (HBV) infection reactivation is associated with high morbidity and mortality in patients with haematologic malignancy and/or haematopoietic stem cell transplantation (HSCT). However, information on this issue is limited. The scope of this position paper is to provide recommendations on HBV screening, monitoring, prophylaxis, treatment and vaccination in the patients described above. METHODS: These recommendations were developed from one meeting of experts attended by different Italian scientific societies as well as from a systematic literature review (of articles published through December 31, 2016) on HBV infection in haematologic patients and in patients who underwent haematopoietic stem cell transplantation published in the same issue of the journal. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess each recommendation's quality. QUESTIONS ADDRESSED: These recommendations provide the answers to the following questions: (a) HBV screening and monitoring: Who should be screened before chemotherapy? Which screening tests should be used? Should HBV-DNA detection be used to monitor HBV reactivation before starting antivirals? What is the best timeline to monitor HBV reactivation? (b) Prophylaxis in HBsAg-positive patients: Which antiviral drugs should be used to treat HBsAg-positive patients? How long should antiviral prophylaxis be provided to HBsAg-positive patients? (c) Prophylaxis in patients with resolved HBV infection: Which patients with resolved HBV infection should receive antiviral prophylaxis? Which antiviral drug should be used? How long should antiviral prophylaxis be provided? (d) HBV infection management strategy in autologous (auto-HSCT) and allogeneic HSCT (allo-HSCT): Which HSCT recipients should receive antiviral prophylaxis? Which antiviral drug should be used? How long should antiviral prophylaxis be provided? (e) Choice of antiviral drugs in the treatment of HBV reactivation: Should third-generation anti-HBV drugs be preferred to first- or second-generation antiviral drugs in the treatment of HBV reactivation with or without hepatitis flare in haematologic patients? (f) Immunization against HBV in patients with haematologic malignancies and/or patients who underwent HSCT: Should these patients be vaccinated? Which HBV vaccination schedule should be adopted? RECOMMENDATIONS: Haematologic patients should be screened for hepatitis B surface antigen (HBsAg) plus anti-hepatitis B core protein (HBc), and HBV DNA before chemotherapy. HBV DNA levels should be monitored monthly in all HBV-positive patients who do not receive prophylaxis. HBsAg-positive haematologic patients and those undergoing HSCT should receive third-generation antiviral therapy as prophylaxis. Anti-HBc-positive lymphoma patients and those receiving HSCT should receive antiviral prophylaxis. All HBV-negative haematologic patients should be vaccinated for HBV. The acquisition of data from well-designed studies is desirable in the near future.

7 Guideline Position paper on treatment of hepatitis C in Romania, 2017. Part one. 2017

Gheorghe, Liana / Sporea, Ioan / Iacob, Speranţa / Şirli, Roxana / Trifan, Anca / Dobru, Daniela / Diculescu, Mircea / Stanciu, Carol / Pascu, Oliviu / Acalovschi, Monica / Brisc, Ciprian / Cijevschi, Cristina / Gheorghe, Cristian / Spârchez, Zeno / Rogoveanu, Ion / Dumitrascu, Dan. ·Center for Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. · Dept. of Gastroenterology and Hepatology, Victor Babeș University of Medicine and Pharmacy, Timișoara, Romania. · Center for Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. msiacob@gmail.com. · Institute of Gastroenterology and Hepatology, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania. · Gastroenterology Department, University of Medicine and Pharmacy, Târgu Mureș, Romania. · Prof. Dr. Octavian Fodor Regional Institute of Gastroenterology and Hepatology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. · Gastroenterology Department, Faculty of Medicine and Pharmacy, Oradea, Romania. · Gastroenterology Department, University of Medicine and Pharmacy, Craiova, Romania. · 2nd Medical Clinic, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. ·J Gastrointestin Liver Dis · Pubmed #28617888.

ABSTRACT: BACKGROUND AND AIMS: Hepatitis C Virus (HCV) infection is a common condition with endemic prevalence in some areas of the world. In Romania the mean prevalence is about 3%. New treatments became available on the market in recent years and new drugs are in the pipeline. A re-evaluation of HCV therapy was considered mandatory. The Romanian Society of Gastroenterology and Hepatology undertook this task for the practitioners of this country. METHODOLOGY: A group of recognized experts was created who screened the available literature and the major available guidelines. A list of items requiring attention has been created. These items were discussed and rated. Decisions were taken by consensus. RECOMMENDATIONS: We present here the first of the two parts of our Society's recommendations for chronic HCV infection treatment. An agreement was reached regarding the diagnostic tools, the assessment of severity and the up-dated therapy schedules. CONCLUSIONS: This Position Paper represents a guide for the assessment and the therapy of HCV infection. The recommendations are in concordance with other guidelines but are applied to the real-life conditions in this country.

8 Guideline Recommendations on hepatitis C screening for adults. 2017

Grad, Roland / Thombs, Brett / Tonelli, Marcello / Bacchus, Maria / Birtwhistle, Richard / Klarenbach, Scott / Singh, Harminder / Dorais, Veronique / Holmes, Nathalie / Martin, Wendy / Rodin, Rachel / Jaramillo Garcia, Alejandra / Anonymous8111110. ·Department of Family Medicine, McGill University, Montréal, Que. · Department of Psychiatry, McGill University, Montréal, Que. · Department of Medicine, University of Calgary, Calgary, Alta. · Departments of Family Medicine and Public Health Sciences, Queen’s University, Kingston, Ont. · Department of Medicine, University of Alberta, Edmonton, Alta. · Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg, Man. · Public Health Agency of Canada, Ottawa, Ont. ·CMAJ · Pubmed #28438952.

ABSTRACT: -- No abstract --

9 Guideline International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. 2017

Terrault, Norah A / Berenguer, Marina / Strasser, Simone I / Gadano, Adrian / Lilly, Les / Samuel, Didier / Kwo, Paul Y / Agarwal, Kosh / Curry, Michael P / Fagiuoli, Stefano / Fung, James Y Y / Gane, Edward / Brown, Kimberly A / Burra, Patrizia / Charlton, Michael / Pessoa, Mario G / McCaughan, Geoff W. ·1 Hepatology and Transplant Surgery, University of California San Francisco, San Francisco, CA. 2 Liver Unit, Hospital Universitario y Politécnico La Fe, Universidad Valencia and CIBEREHD, Valencia, Spain. 3 Australian National Liver Transplant Unit, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia. 4 Liver Unit, Hospital Italiano, Buenos Aires, Argentina. 5 Multiorgan Transplant, University Health Network/Toronto General Hospital, Toronto Hospital, Toronto, Ontario, Canada. 6 Hepatology, AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Univ Paris-Sud, Université Paris-Saclay, Villejuif, France. 7 Department of Medicine, Stanford University, Palo Alto, CA. 8 Institute of Liver Studies, Kings College Hospital, London, United Kingdom. 9 Liver Center, Beth Israel Deaconess Medical Center, Boston, MA. 10 Gastroenterology and Transplant Hepatology, Papa Giovanni XXIII Hospital, Begamo, Italy. 11 The Liver Transplant Center, Queen Mary Hospital, Hong Kong. 12 New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand. 13 Division of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI. 14 Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padova University Hospital, Padova, Italy. 15 Utah Intermountain Transplant and Regenerative Medicine Center, Salt Lake City, UT. 16 Division of Gastroenterology and Hepatology, University of São Paulo School of Medicine, São Paulo, Brazil. 17 Australian National Liver Transplant Unit, Centenary Research Institute, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia. ·Transplantation · Pubmed #28437388.

ABSTRACT: -- No abstract --

10 Guideline International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. 2017

Terrault, Norah A / McCaughan, Geoff W / Curry, Michael P / Gane, Edward / Fagiuoli, Stefano / Fung, James Y Y / Agarwal, Kosh / Lilly, Les / Strasser, Simone I / Brown, Kimberly A / Gadano, Adrian / Kwo, Paul Y / Burra, Patrizia / Samuel, Didier / Charlton, Michael / Pessoa, Mario G / Berenguer, Marina. ·1 Hepatology and Transplant Surgery, University of California San Francisco, San Francisco, CA. 2 Australian National Liver Transplant Unit, Centenary Research Institute, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia. 3 Liver Center, Beth Israel Deaconess Medical Center, Boston, MA. 4 New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand. 5 Gastroenterology and Transplant Hepatology, Papa Giovanni XXIII Hospital, Begamo, Italy. 6 The Liver Transplant Center, Queen Mary Hospital, High West, Hong Kong. 7 Institute of Liver Studies, Kings College Hospital, London, United Kingdom. 8 Multiorgan Transplant, University Health Network/Toronto General Hospital, Toronto, Ontario, Canada. 9 Australian National Liver Transplant Unit, Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia. 10 Division of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI. 11 Liver Unit, Hospital Italiano, Buenos Aires, Argentina. 12 Department of Medicine, Stanford University, Palo Alto, CA. 13 Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padova University Hospital, Padova, Italy. 14 Hepatology, AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Univ Paris-Sud, Université Paris-Saclay, Villejuif, France. 15 Utah Intermountain Transplant and Regenerative Medicine Center, Salt Lake City, UT. 16 Division of Gastroenterology and Hepatology, University of São Paulo School of Medicine, São Paulo, Brazil. 17 Liver Unit, Hospital Universitario y Politécnico La Fe, Universidad Valencia and CIBEREHD, Valencia, Spain. ·Transplantation · Pubmed #28437387.

ABSTRACT: -- No abstract --

11 Guideline EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. 2017

Anonymous1041126 / Anonymous1051126. · ·J Hepatol · Pubmed #28427875.

ABSTRACT: Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection. Chronic HBV infection can be classified into five phases: (I) HBeAg-positive chronic infection, (II) HBeAg-positive chronic hepatitis, (III) HBeAg-negative chronic infection, (IV) HBeAg-negative chronic hepatitis and (V) HBsAg-negative phase. All patients with chronic HBV infection are at increased risk of progression to cirrhosis and hepatocellular carcinoma (HCC), depending on host and viral factors. The main goal of therapy is to improve survival and quality of life by preventing disease progression, and consequently HCC development. The induction of long-term suppression of HBV replication represents the main endpoint of current treatment strategies, while HBsAg loss is an optimal endpoint. The typical indication for treatment requires HBV DNA >2,000IU/ml, elevated ALT and/or at least moderate histological lesions, while all cirrhotic patients with detectable HBV DNA should be treated. Additional indications include the prevention of mother to child transmission in pregnant women with high viremia and prevention of HBV reactivation in patients requiring immunosuppression or chemotherapy. The long-term administration of a potent nucleos(t)ide analogue with high barrier to resistance, i.e., entecavir, tenofovir disoproxil or tenofovir alafenamide, represents the treatment of choice. Pegylated interferon-alfa treatment can also be considered in mild to moderate chronic hepatitis B patients. Combination therapies are not generally recommended. All patients should be monitored for risk of disease progression and HCC. Treated patients should be monitored for therapy response and adherence. HCC remains the major concern for treated chronic hepatitis B patients. Several subgroups of patients with HBV infection require specific focus. Future treatment strategies to achieve 'cure' of disease and new biomarkers are discussed.

12 Guideline Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC): summary of conclusions and recommendations, 1–2 February 2017 meeting. 2017

Anonymous770904. · ·Wkly Epidemiol Rec · Pubmed #28413874.

ABSTRACT: -- No abstract --

13 Guideline American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. 2017

Jacobson, Ira M / Lim, Joseph K / Fried, Michael W. ·Department of Medicine, Mount Sinai Beth Israel Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: ijacobson@chpnet.org. · Section of Digestive Diseases and Yale Liver Center, Yale University School of Medicine, New Haven, Connecticut. · Division of Gastroenterology and Hepatology, UNC Liver Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina. ·Gastroenterology · Pubmed #28344022.

ABSTRACT: Chronic hepatitis C virus infection is well-recognized as a common blood-borne infection with global public health impact affecting 3 to 5 million persons in the United States and more than 170 million persons worldwide. Chronic hepatitis C virus infection is associated with significant morbidity and mortality due to complications of liver cirrhosis and hepatocellular carcinoma. Current therapies with all-oral direct-acting antiviral agents are associated with high rates of sustained virologic response (SVR), generally exceeding 90%. SVR is associated with a reduced risk of liver cirrhosis, hepatic decompensation, need for liver transplantation, and both liver-related and all-cause mortality. However, a subset of patients who achieve SVR will remain at long-term risk for progression to cirrhosis, liver failure, hepatocellular carcinoma, and liver-related mortality. Limited evidence is available to guide clinicians on which post-SVR patients should be monitored vs discharged, how to monitor and with which tests, how frequently should monitoring occur, and for how long. In this clinical practice update, available evidence and expert opinion are used to generate best practice recommendations on the care of patients with chronic hepatitis C virus who have achieved SVR.

14 Guideline No. 342-Hepatitis B and Pregnancy. 2017

Castillo, Eliana / Murphy, Kellie / van Schalkwyk, Julie. ·Calgary, AB. · Toronto, ON. · Vancouver, BC. ·J Obstet Gynaecol Can · Pubmed #28284515.

ABSTRACT: OBJECTIVE: To review the epidemiology, natural history, evaluation, and treatment of hepatitis B virus (HBV) infection during pregnancy. This will aid obstetric care providers in counseling their patients regarding perinatal risks and management options available to pregnant women with hepatitis B. OUTCOMES: Outcomes evaluated include thresholds for HBV anti-viral treatment for prevention of perinatal transmission and for invasive procedures during pregnancy for women with hepatitis B infection. EVIDENCE: Medline, EMBASE, and CINAHL were searched for articles in English on subjects related to HBV infection, pregnancy, and perinatal transmission from 1966 to March 2016. Results were restricted to systematic reviews, randomized controlled trials/controlled clinical trials, and observational studies. Other (unpublished) literature was identified through searching the websites of health technology assessment and health technology assessment-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical speciality societies. VALIDATION METHODS: The quality of the evidence is rated using the criteria described in the Report of the Canadian Task Force on Preventive Health Care (Table 1). Recommendations for practice are ranked according to the method described in this Report. GUIDELINE UPDATE: The guideline will be reviewed 5 years after publication to decide if an update is required. However, if important new evidence is published prior to the 5-year cycle, the review process may be accelerated for a more rapid update of some recommendations. SPONSORS: This guideline was developed with resources funded by the Society of Obstetricians and Gynaecologists of Canada.

15 Guideline Practice Alert: ACIP vaccine update, 2017. 2017

Campos-Outcalt, Doug. ·Medical Director, Mercy Care Plan, Phoenix, AZ, USA. Email:campos-outcaltd@mercycareplan.com. ·J Fam Pract · Pubmed #28249054.

ABSTRACT: HIV infection is now an indication for meningococcus vaccination and HPV vaccine dosing is simpler for patients ⟨15 years.

16 Guideline ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. 2017

Farraye, Francis A / Melmed, Gil Y / Lichtenstein, Gary R / Kane, Sunanda V. ·Section of Gastroenterology, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA. · Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA. · Division of Gastroenterology, Hospital of the University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. · Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. ·Am J Gastroenterol · Pubmed #28071656.

ABSTRACT: Recent data suggest that inflammatory bowel disease (IBD) patients do not receive preventive services at the same rate as general medical patients. Patients with IBD often consider their gastroenterologist to be the primary provider of care. To improve the care delivered to IBD patients, health maintenance issues need to be co-managed by both the gastroenterologist and primary care team. Gastroenterologists need to explicitly inform the primary care provider of the unique needs of the IBD patient, especially those on immunomodulators and biologics or being considered for such therapy. In particular, documentation of up to date vaccinations are crucial as IBD patients are often treated with long-term immune-suppressive therapies and may be at increased risk for infections, many of which are preventable with vaccinations. Health maintenance issues addressed in this guideline include identification, safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, melanoma and non-melanoma skin cancer as well as identification of depression and anxiety and smoking cessation. To accomplish these health maintenance goals, coordination between the primary care provider, gastroenterology team and other specialists is necessary.

17 Guideline  Joint Society statement for elimination of viral hepatitis. 2017

Brahm, Javier / Castera, Laurent / Hou, Jinlin / Lindor, Keith. ·Latin American Association for the Study of the Liver. · European Association of the Study of the Liver. · Asian Pacific Association for the Study of the Liver. · American Association for the Study of Liver Disease. ·Ann Hepatol · Pubmed #28051786.

ABSTRACT: -- No abstract --

18 Guideline ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. 2017

Kwo, Paul Y / Cohen, Stanley M / Lim, Joseph K. ·Division of Gastroenterology/Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA. · Digestive Health Institute, University Hospitals Cleveland Medical Center and Division of Gastroenterology and Liver Disease, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. · Yale Viral Hepatitis Program, Yale University School of Medicine, New Haven, Connecticut, USA. ·Am J Gastroenterol · Pubmed #27995906.

ABSTRACT: Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests should be termed liver chemistries or liver tests. Hepatocellular injury is defined as disproportionate elevation of AST and ALT levels compared with alkaline phosphatase levels. Cholestatic injury is defined as disproportionate elevation of alkaline phosphatase level as compared with AST and ALT levels. The majority of bilirubin circulates as unconjugated bilirubin and an elevated conjugated bilirubin implies hepatocellular disease or cholestasis. Multiple studies have demonstrated that the presence of an elevated ALT has been associated with increased liver-related mortality. A true healthy normal ALT level ranges from 29 to 33 IU/l for males, 19 to 25 IU/l for females and levels above this should be assessed. The degree of elevation of ALT and or AST in the clinical setting helps guide the evaluation. The evaluation of hepatocellular injury includes testing for viral hepatitis A, B, and C, assessment for nonalcoholic fatty liver disease and alcoholic liver disease, screening for hereditary hemochromatosis, autoimmune hepatitis, Wilson's disease, and alpha-1 antitrypsin deficiency. In addition, a history of prescribed and over-the-counter medicines should be sought. For the evaluation of an alkaline phosphatase elevation determined to be of hepatic origin, testing for primary biliary cholangitis and primary sclerosing cholangitis should be undertaken. Total bilirubin elevation can occur in either cholestatic or hepatocellular diseases. Elevated total serum bilirubin levels should be fractionated to direct and indirect bilirubin fractions and an elevated serum conjugated bilirubin implies hepatocellular disease or biliary obstruction in most settings. A liver biopsy may be considered when serologic testing and imaging fails to elucidate a diagnosis, to stage a condition, or when multiple diagnoses are possible.

19 Guideline Post-exposure prophylaxis guidelines for children and adolescents potentially exposed to HIV. 2017

Bamford, Alasdair / Tudor-Williams, Gareth / Foster, Caroline. ·Department of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children NHS Trust, London, UK. · Department of Paediatric Infectious Diseases, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK. ·Arch Dis Child · Pubmed #27974330.

ABSTRACT: UK guidelines for HIV post-exposure prophylaxis (PEP) in adults have recently been updated. Indications for PEP have been modified and there has been a change in the recommended antiretroviral therapy for adults to a combination of raltegravir with tenofovir and emtricitabine (Truvada). Raltegravir and tenofovir are now available in paediatric formulations and offer improved safety and tolerability over previously recommended ritonavir-boosted lopinavir with zidovudine. This guideline provides recommendations for those caring for children potentially exposed to HIV and other bloodborne viruses in primary care, emergency departments, secondary care and specialist paediatric HIV centres.

20 Guideline [Management following sexual exposure to HIV, HVB and HVC]. 2016

Timsit, F-J / Vernay-Vaisse, C / Derancourt, C / Viraben, R / Chartier, C / Spenatto, N / Anonymous12440885. ·Centre clinique et biologique des MST, hôpital Saint-Louis, 42, rue Bichat, 75010 Paris, France. Electronic address: centre.mst@aphp.fr. · CIDAG/CIDDIST MDS Aubagne, 10, allée Antide-Boyer, 13400 Aubagne, France. · Service de dermatologie, CHU de Fort-de-France, 97261 Fort de France, France. · Service de dermatologie et médecine sociale, pôle santé publique et médecine sociale, hôpital La Grave, place Lange, TSA 60033, 31059 Toulouse cedex 9, France. · 24, place Kléber, 67000 Strasbourg, France. ·Ann Dermatol Venereol · Pubmed #27776810.

ABSTRACT: -- No abstract --

21 Guideline [STD and STI screening]. 2016

Vernay-Vaïsse, C / Spenatto, N / Derancourt, C / Timsit, F-J / Fouéré, S / Pinault, A-L / Anonymous11440885. ·CIDAG/CIDDIST CD 13, DPMISP, 4, quai d'Arenc, CS 70095, 13304 Marseille cedex 02, France. Electronic address: chantal.vernayvaisse@cg13.fr. · Pôle santé publique et médecine sociale, service de dermatologie et médecine sociale, hôpital La-Grave, place Lange, TSA 60033, 31059 Toulouse cedex 9, France. · Service de dermatologie, CHU de Fort-de-France, 97261 Fort-de-France, Martinique. · Centre clinique et biologique des MST, hôpital Saint-Louis, 42, rue Bichat, 75010 Paris, France. · 41, boulevard Henri IV, 75004 Paris, France. · Service de dermatologie, hôpital de Brabois, CHU de Nancy, 5, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France. ·Ann Dermatol Venereol · Pubmed #27773502.

ABSTRACT: -- No abstract --

22 Guideline Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries. 2016

Easterbrook, Philippa J / Anonymous1501097. ·Global Hepatitis Programme, HIV Department, World Health Organization, Geneva, Switzerland. Electronic address: easterbrookp@who.int. · Global Hepatitis Programme, HIV Department, World Health Organization, Geneva, Switzerland. ·J Hepatol · Pubmed #27641988.

ABSTRACT: Testing and diagnosis of hepatitis C virus (HCV) infection is the gateway for access to both treatment and prevention services, and crucial for an effective hepatitis epidemic response. In contrast to HIV, a systematic approach to hepatitis C testing has been fragmented and limited to a few countries, and there remains a large burden of undiagnosed cases globally. Key challenges in the current hepatitis testing response, include lack of simple, reliable, and low cost diagnostic tests, laboratory capacity, and testing facilities; inadequate data to guide country-specific hepatitis testing approaches and who to test; stigmatization and social marginalization of some groups with or at risk of viral hepatitis; and lack of international or national guidelines on hepatitis testing for resource-limited settings. New tools to support the hepatitis global response include the 2016 Global Hepatitis Health Sector Strategy which include targets for testing and diagnosis, and World Health Organization (WHO) 2016 hepatitis testing guidelines for adults, adolescents, and children in low- and middle-income countries. The testing guidance complements recent published WHO guidance on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These testing guidelines outline the public health approach to strengthening and expanding current testing practices for HCV and HBV and address what serological and virological assays to use, and who to test, as well as interventions to promote linkage to prevention and care after testing. They are intended for use across all age groups and populations. See boxes for key recommendations. Future directions and innovations in viral hepatitis testing include use of point-of-care assays for nucleic acid testing (NAT) and core antigen; validation of dried blood spots specimens with different commercial serological and NAT assays; multiplex and polyvalent platforms for integrated testing of HIV, HBV and HCV; and potential for self-testing.

23 Guideline SASLT guidelines: Update in treatment of Hepatitis C virus infection. 2016

Alghamdi, Abdullah S / Alghamdi, Mohammed / Sanai, Faisal M / Alghamdi, Hamdan / Aba-Alkhail, Faisal / Alswat, Khalid / Babatin, Mohammed / Alqutub, Adel / Altraif, Ibrahim / Alfaleh, Faleh. ·Department of Medicine, Gastroenterology Unit, King Fahad Hospital, Jeddah, Saudi Arabia. · Department of Medicine, Division of Gastroenterology, King Fahd Military Complex, Dhahran, Saudi Arabia. · Department of Medicine, Division of Gastroenterology, King Abdulaziz Medical City, National Guard Health Affairs, Jeddah, Saudi Arabia. · Department of Hepatobiliary Sciences and Liver Transplantation King Abdulaziz Medical City, and King Saud bin Abdulaziz University for Health Sciences, National Guard Health Affairs, Riyadh, Saudi Arabia. · Department of Medicine, Division of Gastroenterology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. · Department of Medicine, Gastroenterology unit, College of Medicine, King Saud University, Riyadh, Saudi Arabia. · Department of Medical Specialties, Gastroenterology and Hepatology Section, King Fahad Medical City, Riyadh, Saudi Arabia. ·Saudi J Gastroenterol · Pubmed #27538727.

ABSTRACT: -- No abstract --

24 Guideline British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. 2016

Warren, R B / Weatherhead, S C / Smith, C H / Exton, L S / Mohd Mustapa, M F / Kirby, B / Yesudian, P D. ·The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester, M6 8HD, U.K. · Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, U.K. · St John's Institute of Dermatology, Guy's and St Thomas NHS Foundation Trust, London, SE1 9RT, U.K. · British Association of Dermatologists, Willan House, 4 Fitzroy Square, London, W1T 5HQ, U.K. · St Vincent's University Hospital, Elm Park, Dublin, Ireland. · Glan Clwyd Hospital, Sarn Lane, Rhyl, LL18 5UJ, U.K. ·Br J Dermatol · Pubmed #27484275.

ABSTRACT: -- No abstract --

25 Guideline APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. 2016

Omata, Masao / Kanda, Tatsuo / Wei, Lai / Yu, Ming-Lung / Chuang, Wang-Long / Ibrahim, Alaaeldin / Lesmana, Cosmas Rinaldi Adithya / Sollano, Jose / Kumar, Manoj / Jindal, Ankur / Sharma, Barjesh Chander / Hamid, Saeed S / Dokmeci, A Kadir / Al-Mahtab, Mamun / McCaughan, Geofferey W / Wasim, Jafri / Crawford, Darrell H G / Kao, Jia-Horng / Yokosuka, Osamu / Lau, George K K / Sarin, Shiv Kumar. ·Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu-shi, Yamanashi, 400-8506, Japan. momata-tky@umin.ac.jp. · The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. momata-tky@umin.ac.jp. · Graduate School of Medicine, Chiba University, Chiba, Japan. · Peking University People's Hospital, Peking University Hepatology Institute, Beijing, China. · Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan. · Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. · GI/Liver Division, Department of Internal Medicine, University of Benha, Banha, Egypt. · Digestive Disease and GI Oncology Center, Medistra Hospital, University of Indonesia, Jakarta, Indonesia. · University Santo Tomas Hospital, Manila, Philippines. · Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India. · Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India. · Department of Medicine, Aga Khan University and Hospital, Stadium Road, Karachi, 74800, Pakistan. · Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. · Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh. · Royal Prince Alfred Hospital, Centenary Institute, University of Sydney, Sydney, Australia. · University of Queensland, School of Medicine, Woolloongabba, QLD, 4102, Australia. · National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan. · The Institute of Translational Hepatology, Beijing 302 Hospital, Beijing, China. ·Hepatol Int · Pubmed #27229718.

ABSTRACT: The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on "APASL consensus statements and recommendations for management of hepatitis C" in March 2015 to revise the "APASL consensus statements and management algorithms for hepatitis C virus infection" (Hepatol Int 6:409-435, 2012). The working party consisted of expert hepatologists from the Asian-Pacific region gathered at the Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed, and debated during the course of drafting a revision. Participants of the consensus meeting assessed the quality of the cited studies. The finalized recommendations for hepatitis C prevention, epidemiology, and laboratory testing are presented in this review.

Next